Tatton Consulting supported Birmingham-based epigenetics and biomarker discovery company Tagomics in its successful application to Biomedical Catalyst 2024 Round 1: Industry-led R&D, which was awarded £856,657 by Innovate UK for the project InterlACE-CRC: highly sensitive, high throughput and cost-effective multi-omic diagnostics for early detection of colorectal cancer and critical precursor.
About the funded R&D project
Tagomics’ Interlace platform is a multiomics workflow that enriches unmethylated DNA for analysis without altering the underlying sequence, producing an information-rich dataset from a blood sample. The project customises the platform for early detection of colorectal cancer, targeting high sensitivity and specificity at high throughput, followed by a pilot study with the NHS. Detecting the disease earlier matters because colorectal cancer is considerably more treatable before it progresses.
Award details
- Grant awarded: £856,657
- Competition: Biomedical Catalyst 2024 Round 1: Industry-led R&D
- Competition year: 2024/25
- Project: InterlACE-CRC: highly sensitive, high throughput and cost-effective multi-omic diagnostics for early detection of colorectal cancer and critical precursor
- Sector: Cancer diagnostics / epigenetics
- UKRI project record: Gateway to Research, project 10142117
- Dataset: Innovate UK funded projects, published 10 August 2026
Tatton Consulting supported the competitive grant application. The award value, competition and project title above are taken from UKRI’s published record for this project.
See all Innovate UK awards Tatton Consulting has supported on our grant successes page.
